Seroatlas · Human Serome Atlas

LYVE1

Lymphatic vessel endothelial hyaluronic acid receptor 1

Also known as: LYVE-1, LYVE1_HUMAN, XLKD1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9Y5Y7
Gene: LYVE1
Ensembl: ENSG00000133800
Chromosome: 11
Canonical length: 322 aa
Protein class: Plasma proteins, Predicted membrane proteins, Transporters
Quaternary structure: Homodimer

OverviewNCBI Gene

This gene encodes a type I integral membrane glycoprotein. The encoded protein acts as a receptor and binds to both soluble and immobilized hyaluronan. This protein may function in lymphatic hyaluronan transport and have a role in tumor metastasis. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

322 residues, UniProt reviewed canonical sequence.

>Q9Y5Y7|LYVE1
     1  MARCFSLVLL LTSIWTTRLL VQGSLRAEEL SIQVSCRIMG ITLVSKKANQ QLNFTEAKEA
    61  CRLLGLSLAG KDQVETALKA SFETCSYGWV GDGFVVISRI SPNPKCGKNG VGVLIWKVPV
   121  SRQFAAYCYN SSDTWTNSCI PEIITTKDPI FNTQTATQTT EFIVSDSTYS VASPYSTIPA
   181  PTTTPPAPAS TSIPRRKKLI CVTEVFMETS TMSTETEPFV ENKAAFKNEA AGFGGVPTAL
   241  LVLALLFFGA AAGLGFCYVK RYVKAFPFTN KNQQKEMIET KVVKEEKAND SNPNEESKKT
   301  DKNPEESKSP SKTTVRCLEA EV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LYVE1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.5
Highest tissue expression: 140 nTPM

Expression across tissuesHPA

Tissue

placenta: 140 nTPM
adipose tissue: 118 nTPM
adrenal gland: 65 nTPM
smooth muscle: 63 nTPM
spleen: 58 nTPM
liver: 41 nTPM

Single-cell type

hofbauer cells: 1,969 nCPM
kupffer cells: 993 nCPM
lymphatic endothelial cells: 567 nCPM
macrophages: 401 nCPM
monocytes: 95 nCPM
astrocytes: 50 nCPM

Immune cell

neutrophil: 0.2 nTPM
intermediate monocyte: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM

Brain region

choroid plexus: 16 nTPM
cerebral cortex: 8.7 nTPM
basal ganglia: 5.7 nTPM
thalamus: 5.6 nTPM
white matter: 5 nTPM
medulla oblongata: 4.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.35
gnomAD pLI: 0
gnomAD missense Z: 0.19
DepMap mean gene effect: 0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LYVE1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LYVE1 as an antibody target. Whether an autoantibody or antibody against LYVE1 could matter depends on whether native LYVE1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LYVE1 is annotated at the cell surface, where native LYVE1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LYVE1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...